Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller may reduce Post-Surgery nausea in women

NCT ID NCT07026162

Symptom relief Sponsor: YanYing Xiao Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the painkiller oliceridine causes less nausea and vomiting than the standard drug sufentanil in women undergoing gynecologic laparoscopic surgery. Ninety-six participants received one of the two drugs during and after surgery. Researchers tracked nausea, vomiting, and side effects for 48 hours after the operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oliceridine (also known as TRV130 or Olinvyk)
What this could lead to
If oliceridine works better, it could offer a new option for pain control with less nausea and vomiting after gynecologic surgery.
What could go wrong
This is a small, completed phase 4 trial with only 96 participants. Results may not apply to all patients, and oliceridine may not prove superior to the standard drug sufentanil.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

96 people

The number who actually took part.

Started

Jul 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Elective gynecological laparoscopic surgery; 2. Age 18-65 years; 3. ASA physical status I-III; 4. Body mass index (BMI) 18-30 kg/m². Exclusion criteria: 1. Severe dysfunction of major organs such as the heart, lungs, or brain; 2. History of allergy to opioid drugs, propofol, soybeans, or eggs; 3. Recent use of sedatives, analgesics, or monoamine oxidase inhibitors; 4. History of alcohol abuse; 5. Obstructive sleep apnea syndrome; 6. Difficult airway; 7. Psychiatric or neurological disorders; communication disorders; 8. Women who are lactating or pregnant. Withdrawal criteria: 1. Subject requests withdrawal or withdraws voluntarily; 2. Change in surgical method requiring combined gastrointestinal surgery; 3. Occurrence of allergy to the investigational drug or life-threatening complications; 4. Reoperation within 48 hours postoperatively due to bleeding or other factors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gynecologic surgical procedures are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postoperative Nausea and Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gynecologic surgical procedures Laparoscopy Postoperative nausea and vomiting (PONV)

Contacts and locations

Locations

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.